Korea’s Top Drug Company Dong-A Under Tax Probe
This article was originally published in PharmAsia News
Executive Summary
A tax investigation of Korea’s leading pharma comes after recent indictments of executives for alleged rebates to doctors and the approval last month of a plan to split the company into two units.